Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published online before print June 18, 2008, doi:10.1212/01.wnl.0000319688.89790.7a)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
01.wnl.0000319688.89790.7av1
71/9/656    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brouwers, N.
Right arrow Articles by Van Broeckhoven, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brouwers, N.
Right arrow Articles by Van Broeckhoven, C.
Received December 22, 2007
Accepted April 28, 2008

Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease

N. Brouwers MSc, K. Sleegers MD, PhD, S. Engelborghs MD, PhD, S. Maurer-Stroh PhD, I. Gijselinck MSc, J. van der Zee PhD, B. A. Pickut MD, PhD, M. Van den Broeck , M. Mattheijssens , K. Peeters , J. Schymkowitz PhD, F. Rousseau PhD, J.-J. Martin MD, PhD, M. Cruts PhD, P. P. De Deyn MD, PhD, and C. Van Broeckhoven PhD, DSc*

From Neurodegenerative Brain Diseases Group (N.B., K.S., I.G., J.v.d.Z., M.V.d.B., M.M., K.P., M.C., C.V.B.), Department of Molecular Genetics and SWITCH Laboratory (S.M.-S., J.S., F.R.), VIB; Laboratory of Neurogenetics (N.B., K.S., I.G., J.v.d.Z., M.V.d.B., M.M., K.P., M.C., C.V.B.), Laboratory of Neurochemistry and Behaviour (S.E., P.P.D.D.), and Laboratory of Neuropathology (J.-J.M.), Institute Born-Bunge; University of Antwerp (N.B., K.S., S.E., I.G., J.v.d.Z., M.V.d.B., M.M., K.P., J.-J.M., M.C., P.P.D.D., C.V.B.), Antwerpen; University of Brussels (VUB) (S.M.-S., J.S., F.R.); and Memory Clinic and Department of Neurology (S.E., B.A.P., P.P.D.D.), Middelheim General Hospital, Antwerpen, Belgium.


* To whom correspondence should be addressed. E-mail: christine.vanbroeckhoven{at}ua.ac.be.

Objective: Loss-of-function mutations in the progranulin gene (PGRN) were identified in frontotemporal lobar degeneration (FTLD) with ubiquitin-immunoreactive neuronal inclusions (FTLD-U). We assessed whether PGRN also contributes to genetic risk for Alzheimer disease (AD) in an extended Belgian AD patient group (n = 779, onset age 74.7 ± 8.7 years).

Methods: A mutation analysis of the PGRN coding region was performed. The effect of missense mutations was assessed using in silico predictions and protein modeling. Risk effects of common genetic variants were estimated by logistic regression analysis and gene-based haplotype association analysis.

Results: We observed seven missense mutations in eight patients (1.3%). Convincing pathogenic evidence was obtained for two missense mutations, p.Cys139Arg and p.Pro451Leu, affecting PGRN protein folding and leading to loss of PGRN by degradation of the misfolded protein. In addition, we showed that PGRN haplotypes were associated with increased risk for AD.

Conclusions: Our data support a role for PGRN in patients with clinically diagnosed Alzheimer disease (AD). Further, we hypothesize that at least some PGRN missense mutations might lead to loss of functional protein. Whether the underlying pathology in our cases proves to be AD, frontotemporal lobar degeneration, or a combination of the two must await further investigations.




This article has been cited by other articles:


Home page
BrainHome page
N. Finch, M. Baker, R. Crook, K. Swanson, K. Kuntz, R. Surtees, G. Bisceglio, A. Rovelet-Lecrux, B. Boeve, R. C. Petersen, et al.
Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members
Brain, March 1, 2009; 132(3): 583 - 591.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by AAN Enterprises, Inc.